Biocardia Inc. painted a largely upbeat picture for the second quarter of 2019, despite tallying a net loss of $3.8 million, up from $3.2 million in the same period a year ago. Among the quarter's highlights were U.S. FDA clearance to market the Advance steerable introducer for cardiac catheter procedures and expansion of the phase III CardiAMP Heart Failure Trial.

The FDA has granted its final approval to the first neurostimulation device designed to treat the symptoms of heart failure. Cvrx Inc.'s Barostim Neo system received premarket approval on Friday for the improvement of symptoms in patients with advanced heart failure who are not eligible for treatment with cardiac resynchronization therapy or other heart failure devices.

Mason, Ohio-based Atricure Inc. has inked an agreement to buy Redwood City, Calif.-based Sentreheart Inc., which has developed and markets the Lariat percutaneous, epicardial suture delivery device for soft tissue closure. The deal includes an upfront payment of $40 million in cash and stock, plus additional payments related to regulatory and reimbursement milestones over the next several years.

Corindus Vascular Robotics Inc. said Thursday that it has agreed to be acquired by Siemens Medical Solutions, a wholly owned subsidiary of Healthineers AG, in a cash deal worth $1.1 billion. The proposed deal would meld Siemens' portfolio of digital and artificial intelligence tools with Corindus' minimally invasive platform for cardiovascular and peripheral disease.